Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
06 2022
Historique:
revised: 07 12 2021
received: 08 11 2021
accepted: 19 12 2021
pubmed: 11 1 2022
medline: 7 6 2022
entrez: 10 1 2022
Statut: ppublish

Résumé

There is substantial interest in immunotherapy and biologicals in IgE-mediated food allergy. We searched six databases for randomized controlled trials about immunotherapy alone or with biologicals (to April 2021) or biological monotherapy (to September 2021) in food allergy confirmed by oral food challenge. We pooled the data using random-effects meta-analysis. We included 36 trials about immunotherapy with 2126 mainly child participants. Oral immunotherapy increased tolerance whilst on therapy for peanut (RR 9.9, 95% CI 4.5.-21.4, high certainty); cow's milk (RR 5.7, 1.9-16.7, moderate certainty) and hen's egg allergy (RR 8.9, 4.4-18, moderate certainty). The number needed to treat to increase tolerance to a single dose of 300 mg or 1000 mg peanut protein was 2. Oral immunotherapy did not increase adverse reactions (RR 1.1, 1.0-1.2, low certainty) or severe reactions in peanut allergy (RR 1,6, 0.7-3.5, low certainty), but may increase (mild) adverse reactions in cow's milk (RR 3.9, 2.1-7.5, low certainty) and hen's egg allergy (RR 7.0, 2.4-19.8, moderate certainty). Epicutaneous immunotherapy increased tolerance whilst on therapy for peanut (RR 2.6, 1.8-3.8, moderate certainty). Results were unclear for other allergies and administration routes. There were too few trials of biologicals alone (3) or with immunotherapy (1) to draw conclusions. Oral immunotherapy improves tolerance whilst on therapy and is probably safe in peanut, cow's milk and hen's egg allergy. More research is needed about quality of life, cost and biologicals.

Sections du résumé

BACKGROUND
There is substantial interest in immunotherapy and biologicals in IgE-mediated food allergy.
METHODS
We searched six databases for randomized controlled trials about immunotherapy alone or with biologicals (to April 2021) or biological monotherapy (to September 2021) in food allergy confirmed by oral food challenge. We pooled the data using random-effects meta-analysis.
RESULTS
We included 36 trials about immunotherapy with 2126 mainly child participants. Oral immunotherapy increased tolerance whilst on therapy for peanut (RR 9.9, 95% CI 4.5.-21.4, high certainty); cow's milk (RR 5.7, 1.9-16.7, moderate certainty) and hen's egg allergy (RR 8.9, 4.4-18, moderate certainty). The number needed to treat to increase tolerance to a single dose of 300 mg or 1000 mg peanut protein was 2. Oral immunotherapy did not increase adverse reactions (RR 1.1, 1.0-1.2, low certainty) or severe reactions in peanut allergy (RR 1,6, 0.7-3.5, low certainty), but may increase (mild) adverse reactions in cow's milk (RR 3.9, 2.1-7.5, low certainty) and hen's egg allergy (RR 7.0, 2.4-19.8, moderate certainty). Epicutaneous immunotherapy increased tolerance whilst on therapy for peanut (RR 2.6, 1.8-3.8, moderate certainty). Results were unclear for other allergies and administration routes. There were too few trials of biologicals alone (3) or with immunotherapy (1) to draw conclusions.
CONCLUSIONS
Oral immunotherapy improves tolerance whilst on therapy and is probably safe in peanut, cow's milk and hen's egg allergy. More research is needed about quality of life, cost and biologicals.

Identifiants

pubmed: 35001400
doi: 10.1111/all.15211
pmc: PMC9303769
doi:

Substances chimiques

Allergens 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Meta-Analysis Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1852-1862

Informations de copyright

© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

JAMA. 2019 Mar 12;321(10):946-955
pubmed: 30794314
JCI Insight. 2019 Nov 14;4(22):
pubmed: 31723064
J Allergy Clin Immunol. 2012 Feb;129(2):448-55, 455.e1-5
pubmed: 22130425
J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9
pubmed: 28091362
J Allergy Clin Immunol. 2010 May;125(5):1165-7
pubmed: 20451043
Eur Ann Allergy Clin Immunol. 2007 Jan;39(1):12-9
pubmed: 17375736
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
N Engl J Med. 2003 Mar 13;348(11):986-93
pubmed: 12637608
Clin Exp Allergy. 2011 Sep;41(9):1297-304
pubmed: 21481024
J Allergy Clin Immunol. 2020 Apr;145(4):1153-1156
pubmed: 31678426
Pediatr Allergy Immunol. 2018 Nov;29(7):762-772
pubmed: 30054934
Lancet. 2019 Jun 1;393(10187):2222-2232
pubmed: 31030987
Allergy. 2014 Jan;69(1):62-75
pubmed: 24205824
Ann Allergy Asthma Immunol. 2017 Mar;118(3):356-364.e3
pubmed: 28087382
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2452-2460.e3
pubmed: 33677077
Hepatogastroenterology. 1998 Jan-Feb;45(19):52-8
pubmed: 9496487
J Allergy Clin Immunol Pract. 2019 Feb;7(2):479-491.e10
pubmed: 30423449
J Allergy Clin Immunol. 2013 Jan;131(1):119-27.e1-7
pubmed: 23265698
Allergy Asthma Proc. 2009 Jul-Aug;30(4):443-8
pubmed: 19288980
Clin Exp Allergy. 2018 Dec;48(12):1584-1593
pubmed: 30288817
Allergy. 2009 Jun;64(6):876-83
pubmed: 19183164
Allergy. 2007 Nov;62(11):1261-9
pubmed: 17919140
J Allergy Clin Immunol. 1992 Aug;90(2):256-62
pubmed: 1500630
Pediatr Allergy Immunol. 2013 Feb;24(1):66-74
pubmed: 22957889
Pediatr Int. 2017 May;59(5):534-539
pubmed: 27914210
J Allergy Clin Immunol Pract. 2015 Jul-Aug;3(4):532-9
pubmed: 25725940
Lancet. 2019 Oct 19;394(10207):1437-1449
pubmed: 31522849
Pediatr Allergy Immunol. 2019 Feb;30(1):81-92
pubmed: 30169915
Ann Allergy Asthma Immunol. 2013 Dec;111(6):523-8
pubmed: 24267363
Allergy Asthma Clin Immunol. 2020 Mar 18;16:20
pubmed: 32206067
JAMA. 2017 Nov 14;318(18):1798-1809
pubmed: 29136445
J Allergy Clin Immunol. 2015 May;135(5):1275-82.e1-6
pubmed: 25528358
J Allergy Clin Immunol. 2005 Nov;116(5):1073-9
pubmed: 16275379
J Clin Epidemiol. 2020 Mar;119:126-135
pubmed: 31711912
Cochrane Database Syst Rev. 2018 Apr 20;4:CD010638
pubmed: 29676439
J Allergy Clin Immunol. 2008 Dec;122(6):1154-60
pubmed: 18951617
Clin Microbiol Infect. 2014 Feb;20(2):123-9
pubmed: 24320992
Lancet. 2014 Apr 12;383(9925):1297-1304
pubmed: 24485709
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):476-485.e3
pubmed: 29092786
Clin Exp Allergy. 2015 Dec;45(12):1833-43
pubmed: 26236997
Arch Dis Child. 2011 Mar;96(3):259-64
pubmed: 20522461
Ann Allergy Asthma Immunol. 2010 Nov;105(5):376-81
pubmed: 21055664
Clin Exp Allergy. 2020 Apr;50(4):420-441
pubmed: 31841239
Clin Exp Allergy. 2018 Jul;48(7):862-874
pubmed: 29665158
Ann Allergy Asthma Immunol. 2020 Nov;125(5):535-542
pubmed: 32569834
Clin Exp Allergy. 2012 Mar;42(3):363-74
pubmed: 22356141
J Allergy Clin Immunol. 2019 Dec;144(6):1584-1594.e2
pubmed: 31319102
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
J Allergy Clin Immunol. 2008 Feb;121(2):343-7
pubmed: 18158176
Allergy. 2022 Jun;77(6):1852-1862
pubmed: 35001400
J Allergy Clin Immunol. 2011 May;127(5):1309-10.e1
pubmed: 21397314
Lancet Child Adolesc Health. 2020 Oct;4(10):728-739
pubmed: 32702315
Allergy. 2017 Aug;72(8):1133-1147
pubmed: 28058751
J Allergy Clin Immunol. 2019 Feb;143(2):651-661.e9
pubmed: 30389226
Acta Paediatr. 2013 Feb;102(2):172-6
pubmed: 22897785
Sci Rep. 2017 Dec 12;7(1):17453
pubmed: 29234055
Allergy. 2018 Apr;73(4):799-815
pubmed: 29205393
Allergol Int. 2018 Apr;67(2):209-216
pubmed: 28778455
Int Arch Allergy Immunol. 2020;181(3):170-182
pubmed: 31801149

Auteurs

Debra de Silva (D)

The Evidence Centre, London, UK.

Pablo Rodríguez Del Río (P)

Niño Jesus University Children's Hospital, Madrid, Spain.

Nicolette W de Jong (NW)

University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Ekaterina Khaleva (E)

University of Southampton, London, UK.

Chris Singh (C)

The Evidence Centre, Wellington, New Zealand.

Anna Nowak-Wegrzyn (A)

NYU Langone Health, New York, New York, USA.

Antonella Muraro (A)

Padua University Hospital, Padua, Italy.

Philippe Begin (P)

Univerisite de Montreal, Montreal, QC, Canada.

Giovanni Pajno (G)

Policlinico Hospital-University of Messina, Messina, Italy.

Alessandro Fiocchi (A)

Bambino Gesù Childrens' Hospital IRCCS, Rome, Italy.

Angel Sanchez (A)

AEPNAA Spanish Association for People with Food and Latex Allergy, Madrid, Spain.

Carla Jones (C)

Allergy UK, London, UK.

Caroline Nilsson (C)

Karolinska Institutet and Sachs´ Children and Youth Hospital, Stockholm, Sweden.

Carsten Bindslev-Jensen (C)

Odense University Hospital, Odense, Denmark.

Gary Wong (G)

Chinese University of Hong Kong, Hong Kong, Hong Kong.

Hugh Sampson (H)

Mount Sinai School of Medicine, New York, New York, USA.

Kirsten Beyer (K)

Charité-Universitätsmedizin Berlin, Berlin, Germany.

Mary-Jane Marchisotto (MJ)

EAACI Patient Organisation Committee Chair, New York, New York, USA.

Montserrat Fernandez Rivas (M)

Hospital Clínico San Carlos, Madrid, Spain.

Rosan Meyer (R)

Imperial College, London, UK.

Susanne Lau (S)

Charité - Universitätsmedizin Berlin, Berlin, Germany.

Ulugbek Nurmatov (U)

Cardiff University, Cardiff, UK.

Graham Roberts (G)

University of Southampton, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH